US Malabsorption Syndrome Market

ID: MRFR/Pharma/11792-CR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026
US Malabsorption Syndrome Market Trends And Share Analysis By Diagnosis (Tests, Imaging), Causative Diseases (Lactose Intolerance, Sprue, Cystic Fibrosis), Treatment (Gluten-Free Diet, Antidiarrheal Agents, Anti-Inflammatory Drugs), End User – Global Forecast Till 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Medical Device, BY causative diseases (USD Million)
      1. 4.1.1 Cystic fibrosis
      2. 4.1.2 Parasitic diseases
      3. 4.1.3 Intestinal disorders
      4. 4.1.4 Celiac disease
      5. 4.1.5 Others
      6. 4.1.6 Lactose intolerance
      7. 4.1.7 Whipple’s disease
      8. 4.1.8 Tropical sprue
      9. 4.1.9 Others
    2. 4.2 Medical Device, BY diagnosis (USD Million)
      1. 4.2.1 Imaging studies
      2. 4.2.2 CT scan
      3. 4.2.3 Endoscopic retrograde cholangiopancreatogram (ERCP)
      4. 4.2.4 Magnetic resonance cholangiopancreatography (MRCP)
      5. 4.2.5 Abdominal x-ray
      6. 4.2.6 Hematologic tests
      7. 4.2.7 Other tests
      8. 4.2.8 Test of fat malabsorption
      9. 4.2.9 Tests of carbohydrate absorption
      10. 4.2.10 Schilling test
      11. 4.2.11 D-xylose test
      12. 4.2.12 Test of bile salt absorption
      13. 4.2.13 C-d-xylose breath test
    3. 4.3 Medical Device, BY treatment (USD Million)
      1. 4.3.1 Gluten-free diet
      2. 4.3.2 Anti-inflammatory drugs
      3. 4.3.3 Antibiotics
      4. 4.3.4 Nutritional supplements
      5. 4.3.5 Protease and lipase supplements
      6. 4.3.6 Antidiarrheal agents
      7. 4.3.7 Others
    4. 4.4 Medical Device, BY end-user (USD Million)
      1. 4.4.1 Hospitals
      2. 4.4.2 Academic and Research Institutes
      3. 4.4.3 Pharmaceutical companies
      4. 4.4.4 Nutrition Clinics
      5. 4.4.5 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Medical Device
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 AbbVie (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Takeda Pharmaceutical Company Limited (JP)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Nestle Health Science (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Johnson & Johnson (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Boehringer Ingelheim (DE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Mylan N.V. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Purdue Pharma L.P. (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Ferring Pharmaceuticals (CH)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY CAUSATIVE DISEASES
    3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS
    4. 6.4 US MARKET ANALYSIS BY TREATMENT
    5. 6.5 US MARKET ANALYSIS BY END-USER
    6. 6.6 KEY BUYING CRITERIA OF MEDICAL DEVICE
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF MEDICAL DEVICE
    9. 6.9 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
    11. 6.11 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
    12. 6.12 MEDICAL DEVICE, BY CAUSATIVE DISEASES, 2024 (% SHARE)
    13. 6.13 MEDICAL DEVICE, BY CAUSATIVE DISEASES, 2024 TO 2035 (USD Million)
    14. 6.14 MEDICAL DEVICE, BY DIAGNOSIS, 2024 (% SHARE)
    15. 6.15 MEDICAL DEVICE, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
    16. 6.16 MEDICAL DEVICE, BY TREATMENT, 2024 (% SHARE)
    17. 6.17 MEDICAL DEVICE, BY TREATMENT, 2024 TO 2035 (USD Million)
    18. 6.18 MEDICAL DEVICE, BY END-USER, 2024 (% SHARE)
    19. 6.19 MEDICAL DEVICE, BY END-USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY CAUSATIVE DISEASES, 2025-2035 (USD Million)
      2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
      3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
      4. 7.2.4 BY END-USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Medical Device Market Segmentation

Medical Device By causative diseases (USD Million, 2025-2035)

  • Cystic fibrosis
  • Parasitic diseases
  • Intestinal disorders
  • Celiac disease
  • Others
  • Lactose intolerance
  • Whipple’s disease
  • Tropical sprue
  • Others

Medical Device By diagnosis (USD Million, 2025-2035)

  • Imaging studies
  • CT scan
  • Endoscopic retrograde cholangiopancreatogram (ERCP)
  • Magnetic resonance cholangiopancreatography (MRCP)
  • Abdominal x-ray
  • Hematologic tests
  • Other tests
  • Test of fat malabsorption
  • Tests of carbohydrate absorption
  • Schilling test
  • D-xylose test
  • Test of bile salt absorption
  • C-d-xylose breath test

Medical Device By treatment (USD Million, 2025-2035)

  • Gluten-free diet
  • Anti-inflammatory drugs
  • Antibiotics
  • Nutritional supplements
  • Protease and lipase supplements
  • Antidiarrheal agents
  • Others

Medical Device By end-user (USD Million, 2025-2035)

  • Hospitals
  • Academic and Research Institutes
  • Pharmaceutical companies
  • Nutrition Clinics
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035